Alzex Neuropharma (Alzex Neuropharma) Revenue : $ Mil (TTM As of . 20)

View and export this data going back to 2011. Start your Free Trial

What is Alzex Neuropharma Revenue?

Alzex Neuropharma's revenue for the three months ended in . 20 was $0.00 Mil. Alzex Neuropharma does not have enough years/quarters to calculate its revenue for the trailing twelve months (TTM) ended in . 20. Alzex Neuropharma's Revenue per Share for the three months ended in . 20 was $0.00. Alzex Neuropharma does not have enough years/quarters to calculate its Revenue per Share for the trailing twelve months (TTM) ended in . 20.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.

Alzex Neuropharma Revenue Historical Data

The historical data trend for Alzex Neuropharma's Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alzex Neuropharma Revenue Chart

Alzex Neuropharma Annual Data

Trend

Revenue

Alzex Neuropharma Quarterly Data

Revenue

Competitive Comparison of Alzex Neuropharma's Revenue

For the Biotechnology subindustry, Alzex Neuropharma's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Alzex Neuropharma's Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alzex Neuropharma's Revenue distribution charts can be found below:

* The bar in red indicates where Alzex Neuropharma's Revenue falls into.

Alzex Neuropharma Revenue Calculation

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

Alzex Neuropharma (OTCPK:TRRI) Revenue Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:

Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.

Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.

Alzex Neuropharma Revenue Related Terms

Thank you for viewing the detailed overview of Alzex Neuropharma's Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Alzex Neuropharma (Alzex Neuropharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alzex Neuropharma Inc (OTCPK:TRRI) » Definitions » Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

8275 South Eastern Avenue, Suite 200-168, Las Vegas, NV, USA, 89123

Website

https://www.trinresinc.com

Alzex Neuropharma Inc is a development-stage biopharmaceutical company that has developed and patented precision therapeutics for the treatment of Alzheimer's Disease and other neurological diseases. The company currently holds two families of patents via an exclusive and unlimited licensing agreement with INSA (Institut National des Sciences Appliquees) a French academic engineering and research institute.

Alzex Neuropharma (Alzex Neuropharma) Headlines

No Headlines